Merck Vioxx Migraine Indication Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The new indication could give Merck an edge in the COX-2 market over Celebrex and Bextra. Pfizer has a pending sNDA for Bextra in migraines.